Log In
Print this Print this

cipargamin (KAE609) (formerly NITD609)

  Manage Alerts
Collapse Summary General Information
Company Novartis AG
DescriptionSynthetic spiroindolone analog
Molecular Target P. falciparum P-type cation-transporter ATPase 4 (PfATP4)
Mechanism of Action 
Therapeutic ModalitySmall molecule
Latest Stage of DevelopmentPhase II
Standard IndicationMalaria
Indication DetailsTreat malaria
Regulatory Designation

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today